Today: 29 January 2026
Subscribe
Browse Category

Biotech Stocks News 30 December 2025 - 13 January 2026

Regencell Bioscience (RGC) stock drops 20% in Nasdaq trade as volatility flares again

Regencell Bioscience (RGC) stock drops 20% in Nasdaq trade as volatility flares again

New York, Jan 13, 2026, 14:12 EST — Regular session Shares of Regencell Bioscience Holdings Limited dropped over 20% on Tuesday, continuing a volatile streak that has kept the Nasdaq-listed microcap in the spotlight on momentum trackers. The decline is significant because the stock has proven it can swing sharply with little notice, a pattern that can catch late buyers…
13 January 2026
····
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

New York, Jan 12, 2026, 14:53 EST — Regular session. Sarepta Therapeutics shares dropped roughly 13% to $20.73 in Monday afternoon trading following a disappointing sales forecast for its Duchenne muscular dystrophy gene therapy, Elevidys, in the fourth quarter. This matters because Elevidys has turned into the company’s key swing factor — and a closely watched one at that —…
12 January 2026
····
NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

New York, January 10, 2026, 18:35 EST — Market closed Shares of NovaBay Pharmaceuticals Inc soared on Friday, closing up roughly 103% at $19.16. Over 10 million shares changed hands, market data showed. NovaBay is back on momentum screens before the next U.S. session, trading in a price range unseen for over a year. Why it matters now: NovaBay’s size…
11 January 2026
·····
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

New York, Jan 9, 2026, 13:28 (EST) — Regular session Soleno Therapeutics shares slid on Friday, extending a choppy stretch for the rare-disease drugmaker. The stock was down 5.6% at $42.95, after touching a low of $42.73, while the SPDR S&P Biotech ETF was up about 1.1%. The move matters now because Soleno’s story still hinges on a young commercial…
9 January 2026
···
Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

New York, Jan 7, 2026, 10:56 EST — Regular session Regencell Bioscience Holdings Limited shares jumped about 27% to $41.90 in morning trading on Wednesday, extending a sharp two-day run for the Nasdaq-listed microcap. The stock has swung between $34.11 and $43.74 so far in the session, with nearly 1.0 million shares traded. Why it matters now: the move builds…
7 January 2026
··
Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

New York, Jan 7, 2026, 11:04 EST — Regular session Shares of Crinetics Pharmaceuticals rose about 16% to $53.40 on Wednesday, after the biotech priced a $350 million stock offering and detailed early U.S. launch metrics for its newly approved acromegaly drug. Crinetics said it generated preliminary, unaudited net product revenue of more than $5 million from PALSONIFY in the…
7 January 2026
·····
Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

NEW YORK, January 4, 2026, 13:49 ET — Market closed Dyne Therapeutics shares closed down 5.5% on Friday at $18.50, ending the first U.S. trading session of 2026 on a softer note. About 2.65 million shares changed hands. The pullback matters because 2026 is shaping up as a timing-driven year for the clinical-stage biotech, with investors focused on whether its…
4 January 2026
·····
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

New York, Jan 4, 2026, 12:46 ET — Market closed Wave Life Sciences shares closed down 6.2% on Friday at $15.95, with the Nasdaq-listed biotech swinging between $15.53 and $17.23 in the session. The drop matters because Wave’s stock has become a high-beta proxy for investor appetite for next-generation obesity treatments, where early clinical signals can move valuations sharply. The…
4 January 2026
·····
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

NEW YORK, December 31, 2025, 18:31 ET — After-hours Corcept Therapeutics Inc shares sank about 50% in after-hours trading on Wednesday after the U.S. Food and Drug Administration declined to approve its oral drug relacorilant for a Cushing’s-related hypertension use. The stock was last at $34.80, down $35.39 from the prior close. Reuters The decision hits at a key moment…
1 January 2026
····
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

NEW YORK, December 31, 2025, 11:19 ET — Regular session Abivax Société Anonyme’s U.S.-listed American depositary shares (ABVX) fell about 3.8% to $133.04, down roughly $5.30 from Tuesday’s close, in late morning trade on Wednesday. The shares opened at $138 and swung between $132.13 and $140.25, with about 348,000 shares traded. The pullback keeps the spotlight on ABVX after takeover…
31 December 2025
····
Why Caris Life Sciences (CAI) stock is down today as biotech slips

Why Caris Life Sciences (CAI) stock is down today as biotech slips

NEW YORK, December 30, 2025, 14:58 ET — Regular session Caris Life Sciences shares were down about 1.8% at $27.44 as of 2:41 p.m. ET, after trading between $27.00 and $27.97 during Tuesday’s session. The drop came as biotech stocks underperformed, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.2%. The…
30 December 2025
···
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

NEW YORK, December 30, 2025, 13:38 ET — Regular session Shares of Mineralys Therapeutics Inc fell 3.3% to $35.61 by early afternoon on Tuesday, after touching a session low of $35.17. About 513,000 shares had changed hands, versus a previous close of $36.83. Mineralys has a market value of about $2.9 billion and remains up about 183% over the past…
30 December 2025
·····
1 2 3 … 6

Stock Market Today

  • Stocks Mixed as Fed Holds Interest Rates Steady, Nasdaq Hits 3-Month High
    January 29, 2026, 12:45 AM EST. Stocks closed mixed on Wednesday after the Federal Reserve (Fed) kept interest rates at 3.50%-3.75%, in line with expectations. The S&P 500 fell slightly from a record high, down 0.01%, while the Nasdaq 100 jumped 0.32% to a three-month peak, buoyed by gains in chipmakers and AI infrastructure stocks. ASML Holding posted record Q4 bookings of 13.2 billion euros, fueling optimism in semiconductor equipment demand. Better-than-expected earnings from Seagate and Texas Instruments also supported market sentiment. The dollar index rebounded after a recent plunge, influenced by President Trump's comments, which also pushed gold prices to a new peak. Meanwhile, oil prices rose to a four-month high amid geopolitical tensions with Iran. Mortgage applications declined by 8.5% last week as the average 30-year mortgage rate increased to 6.24%. The Fed signaled a wait-and-see approach on future rate changes, citing steady economic growth and inflation risks.
Go toTop